Abstract
BACKGROUND AND OBJECTIVES: Escherichia coli (E. coli) sequence type 131 (ST131) is associated with extended-spectrum beta-lactamase (ESBL) production and fluoroquinolone resistance. This study aimed to investigate the prevalence of ST131, ESBL, and plasmid-mediated quinolone resistance (PMQR) genes in the ciprofloxacin-resistant (CIP(R)) and ESBL producers from women with UTI. MATERIALS AND METHODS: The CIP-resistant ESBL producing (CIP(R)/ESBL(+)) E. coli isolates were screened for ST131-by specific PCR of mdh and gyrB. The ESBL and PMQR genes were screened by single PCR. The ST131 and non-ST131 isolates were selected to determine the mutations of gyrA and parC using PCR and sequencing, and also their genetic background by the Pasteur-MLST scheme. RESULTS: Overall, 55% (33/60) CIP(R)/ESBL(+) isolates were identified as ST131 (94% O25b-ST131). Resistance rate to ampicillin-sulbactam (70%), aztreonam (97%) and gentamicin (61%), the prevalence of aac(6')-Ib-cr (66%), bla (CTX-M-15) (82%), the profile of qnrS+aac(6')-Ib-cr (30%), and the double mutation in the parC was significantly higher in ST131 than non- ST131 isolates. The coexistence of PMQR and ESBL genes was found in more than 50% of ST131 and non-ST131 isolates. ST131 isolates differentiated into PST43 and PST506. CONCLUSION: Management of women with UTI caused by the CIP(R)/ESBL(+) isolates (ST131) co-harbored PMQR, ESBL, and chromosomal mutations, is important for their effective therapy.